Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction therapy. This report compares the various salvage treatments and provides guidance in selecting a regimen with the optimum clinical outcome. Regimens using high- dose ara-C (HDAC) in combination with mitoxantrone, amsacrine, or idarubicin are superior to HDAC alone or with L-asparaginase. The sequential administration of methotrexate and L-asparaginase is equally effective. The duration of second CR is short for all chemotherapeutic regimens.

Original languageEnglish (US)
Pages (from-to)341-344
Number of pages4
JournalAmerican Journal of Hematology
Volume45
Issue number4
StatePublished - 1994

Keywords

  • acute lymphoblastic leukemia
  • reinduction regimens
  • remission
  • treatment

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults'. Together they form a unique fingerprint.

  • Cite this